Gamida Cell Ltd (GMDAQ)

[midastouch017]

Gamida Cell Ltd. (NASDAQ:GMDA)

https://finance.yahoo.com/news/10-best-biotech-stocks-under-141250414.html

Number of Hedge Fund Holders: 12

Share Price as of March 28: $4.1265

Headquartered in Jerusalem, Israel, Gamida Cell Ltd. (NASDAQ:GMDA) develops cell therapies for blood cancers, lymphoma, multiple myeloma, and hematologic diseases. It is one of the best cheap biotech stocks to invest in, priced at $4.1265.

On January 19, H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Gamida Cell Ltd. (NASDAQ:GMDA) with a $22 price target. This came in light of the company announcing its successful Type B meeting with the FDA and plans to initiate in the first half of 2022 a rolling Biologics License Application submission for omidubicel, a cell therapy for blood cancer. He calls Gamida Cell Ltd. (NASDAQ:GMDA) a top pick for 2022.

Among the hedge funds tracked by Insider Monkey, 12 funds were bullish on Gamida Cell Ltd. (NASDAQ:GMDA), with combined stakes worth $13.1 million. Rock Springs Capital Management is the biggest shareholder of the company, with 2.15 million shares worth $5.4 million.